Role of ctDNA in predicting the outcome of patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trial

Pretreatment and early dynamics of ctDNA represent promising prognostic and predictive biomarkers in patients with HR+/HER2- ABC treated with ribociclib/letrozole. Early ctDNA dynamic appeared a promising surrogate biomarker for treatment. Further studies are warranted to validate their clinical utility.